By DengYueMed
In the rapidly evolving landscape of China's pharmaceutical industry, the recent update to the National Reimbursement Drug List (NRDL) marks a significant milestone. Announced just yesterday, this revision includes 114 new drugs, enhancing patient access to cutting-edge treatments across various therapeutic areas. As a keen observer of biotech advancements, I delve into how this...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)